Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences By: Gracell Biotechnologies Inc. via GlobeNewswire September 14, 2023 at 09:15 AM EDT SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three upcoming investor conferences. Stifel 2023 Immunology and Inflammation Virtual Summit Fireside Chat: Wednesday, September 20th at 10:15 am ETPresenter: Dr. Kevin Xie, Chief Financial OfficerLocation: Virtual Jefferies Cell & Genetic Medicine SummitFireside Chat: Tuesday, September 26th at 9:00 am ETOne-on-one meetings: September 26th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York 2023 Cantor Global Healthcare ConferencePresentation: Wednesday, September 27th at 9:10 am ETOne-on-one meetings: September 27th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York Webcast of the presentations will be available on the News and Events section of Gracell’s investor website. A replay of the webcast will be available for 30 days following the event. About Gracell Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-cell non-Hodgkin's lymphoma and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn. Media contact Marvin Tang marvin.tang@gracellbio.com Investor contact Gracie Tong gracie.tong@gracellbio.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences By: Gracell Biotechnologies Inc. via GlobeNewswire September 14, 2023 at 09:15 AM EDT SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three upcoming investor conferences. Stifel 2023 Immunology and Inflammation Virtual Summit Fireside Chat: Wednesday, September 20th at 10:15 am ETPresenter: Dr. Kevin Xie, Chief Financial OfficerLocation: Virtual Jefferies Cell & Genetic Medicine SummitFireside Chat: Tuesday, September 26th at 9:00 am ETOne-on-one meetings: September 26th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York 2023 Cantor Global Healthcare ConferencePresentation: Wednesday, September 27th at 9:10 am ETOne-on-one meetings: September 27th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York Webcast of the presentations will be available on the News and Events section of Gracell’s investor website. A replay of the webcast will be available for 30 days following the event. About Gracell Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-cell non-Hodgkin's lymphoma and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn. Media contact Marvin Tang marvin.tang@gracellbio.com Investor contact Gracie Tong gracie.tong@gracellbio.com
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three upcoming investor conferences. Stifel 2023 Immunology and Inflammation Virtual Summit Fireside Chat: Wednesday, September 20th at 10:15 am ETPresenter: Dr. Kevin Xie, Chief Financial OfficerLocation: Virtual Jefferies Cell & Genetic Medicine SummitFireside Chat: Tuesday, September 26th at 9:00 am ETOne-on-one meetings: September 26th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York 2023 Cantor Global Healthcare ConferencePresentation: Wednesday, September 27th at 9:10 am ETOne-on-one meetings: September 27th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York Webcast of the presentations will be available on the News and Events section of Gracell’s investor website. A replay of the webcast will be available for 30 days following the event. About Gracell Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-cell non-Hodgkin's lymphoma and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn. Media contact Marvin Tang marvin.tang@gracellbio.com Investor contact Gracie Tong gracie.tong@gracellbio.com